- Home
- AKBA vs MGIC Comparison
AKBA vs MGIC Comparison
Compare AKBA & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- MGIC
- Stock Information
- Founded
- AKBA 2007
- MGIC 1983
- Country
- AKBA United States
- MGIC Israel
- Employees
- AKBA N/A
- MGIC 3787
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- MGIC Computer Software: Prepackaged Software
- Sector
- AKBA Health Care
- MGIC Technology
- Exchange
- AKBA Nasdaq
- MGIC Nasdaq
- Market Cap
- AKBA 861.7M
- MGIC 1.0B
- IPO Year
- AKBA 2014
- MGIC 1991
- Fundamental
- Price
- AKBA $2.95
- MGIC $20.32
- Analyst Decision
- AKBA Strong Buy
- MGIC Buy
- Analyst Count
- AKBA 5
- MGIC 2
- Target Price
- AKBA $6.90
- MGIC $18.00
- AVG Volume (30 Days)
- AKBA 3.9M
- MGIC 42.7K
- Earning Date
- AKBA 11-06-2025
- MGIC 08-13-2025
- Dividend Yield
- AKBA N/A
- MGIC 2.74%
- EPS Growth
- AKBA N/A
- MGIC 16.93
- EPS
- AKBA N/A
- MGIC 0.78
- Revenue
- AKBA $203,733,000.00
- MGIC $584,528,000.00
- Revenue This Year
- AKBA $38.23
- MGIC $11.11
- Revenue Next Year
- AKBA $38.17
- MGIC $6.83
- P/E Ratio
- AKBA N/A
- MGIC $26.26
- Revenue Growth
- AKBA 16.75
- MGIC 11.98
- 52 Week Low
- AKBA $1.24
- MGIC $10.42
- 52 Week High
- AKBA $4.08
- MGIC $22.00
- Technical
- Relative Strength Index (RSI)
- AKBA 40.51
- MGIC 54.27
- Support Level
- AKBA $2.92
- MGIC $18.72
- Resistance Level
- AKBA $3.15
- MGIC $20.80
- Average True Range (ATR)
- AKBA 0.14
- MGIC 0.50
- MACD
- AKBA 0.01
- MGIC 0.05
- Stochastic Oscillator
- AKBA 18.75
- MGIC 78.05
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.